Matching articles for "Onychomycosis"
Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • October 18, 2021; (Issue 1635)
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include...
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include older age, diabetes, poor peripheral
circulation, smoking, HIV infection, psoriasis, and
immunosuppression. Left untreated, onychomycosis
can cause nail plate destruction, ingrown nails, and
(particularly in patients with diabetes) secondary
infections. Guidelines on treatment of onychomycosis
have been published.
Tavaborole Topical Solution (Kerydin) for Onychomycosis
The Medical Letter on Drugs and Therapeutics • March 2, 2015; (Issue 1463)
The FDA has approved tavaborole 5% solution
(Kerydin – Anacor Pharmaceuticals) for topical treatment
of toenail onychomycosis due to Trichophyton
rubrum or Trichophyton mentagrophytes. It is the
first...
The FDA has approved tavaborole 5% solution
(Kerydin – Anacor Pharmaceuticals) for topical treatment
of toenail onychomycosis due to Trichophyton
rubrum or Trichophyton mentagrophytes. It is the
first oxaborole antifungal drug to be approved for this
indication.
Efinaconazole Topical Solution (Jublia) for Onychomycosis
The Medical Letter on Drugs and Therapeutics • September 15, 2014; (Issue 1451)
The FDA has approved efinaconazole 10% solution
(Jublia – Valeant) for topical treatment of toenail
onychomycosis due to Trichophyton rubrum and/or
Trichophyton mentagrophytes. It is the first...
The FDA has approved efinaconazole 10% solution
(Jublia – Valeant) for topical treatment of toenail
onychomycosis due to Trichophyton rubrum and/or
Trichophyton mentagrophytes. It is the first topical
triazole antifungal drug to be approved for this
indication. A topical oxaborole antifungal solution,
tavaborole 5% (Kerydin – Anacor), also recently
approved by the FDA for the same indication will be
reviewed in a future issue.
Laser Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • February 18, 2013; (Issue 1410)
Fungal infections of the fingernails or toenails can persist
for months or years despite topical and systemic
antimicrobial therapy. The FDA has cleared several
short-pulse laser systems for treatment of...
Fungal infections of the fingernails or toenails can persist
for months or years despite topical and systemic
antimicrobial therapy. The FDA has cleared several
short-pulse laser systems for treatment of this mainly
cosmetic disorder.
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • August 1, 2012; (Issue 120)
The drugs of choice for treatment of fungal infections
are listed in the table that begins on page 62. Some of
the indications and dosages recommended here have
not been approved by the FDA. More detailed...
The drugs of choice for treatment of fungal infections
are listed in the table that begins on page 62. Some of
the indications and dosages recommended here have
not been approved by the FDA. More detailed guidelines
for some of these infections are available online
from the Infectious Diseases Society of America
(www.idsociety.org).
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • December 1, 2009; (Issue 88)
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from...
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from the Infectious Diseases Society of America (www.idsociety.org).
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • January 1, 2008; (Issue 65)
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from...
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America (www.idsociety.org).
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • February 1, 2005; (Issue 30)
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the...
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.
Terbinafine for Onychomycosis
The Medical Letter on Drugs and Therapeutics • August 16, 1996; (Issue 981)
Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment...
Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment of fungal nail infections caused by dermatophytes. Oral terbinafine has been available in Europe since 1992.
Itraconazole for Onychomycosis
The Medical Letter on Drugs and Therapeutics • January 19, 1996; (Issue 966)
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for...
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.